CC
REGN icon

Centiva Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Centiva Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100
Closed -$77.2K – 1952
2025
Q4 		$77.2K Buy
+100
New +$67.9K ﹤0.01% 1102
2025
Q1 		– Sell
-600
Closed -$427K – 2036
2024
Q4 		$427K Hold
600
– – 0.01% 916
2024
Q3 		$631K Sell
600
-600
-50% -$668K 0.01% 1089
2024
Q2 		$1.26M Sell
1,200
-400
-25% -$388K 0.02% 657
2024
Q1 		$1.54M Buy
1,600
+600
+60% +$571K 0.04% 443
2023
Q4 		$878K Sell
1,000
-2,100
-68% -$1.73M 0.02% 680
2023
Q3 		$2.55M Buy
3,100
+500
+19% +$393K 0.06% 321
2023
Q2 		$1.87M Sell
2,600
-900
-26% -$694K 0.04% 407
2023
Q1 		$2.88M Buy
3,500
+2,500
+250% +$1.89M 0.07% 300
2022
Q4 		$721K Sell
1,000
-2,000
-67% -$1.48M 0.02% 665
2022
Q3 		$2.07M Sell
3,000
-4,500
-60% -$2.83M 0.04% 344
2022
Q2 		$4.43M Sell
7,500
-1,000
-12% -$650K 0.11% 164
2022
Q1 		$5.94M Buy
8,500
+7,400
+673% +$4.68M 0.11% 130
2021
Q4 		$695K Buy
+1,100
New +$676K 0.01% 714
2019
Q3 		– Sell
-300
Closed -$94K – 705
2019
Q2 		$94K Sell
300
-42,000
-99% -$14M 0.01% 372
2019
Q1 		$17.4M Buy
42,300
+24,000
+131% +$9.88M 1.17% 11
2018
Q4 		$6.83M Buy
+18,300
New +$6.7M 0.54% 27

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Centiva Capital's REGN Position: Q1 2026 in Review

Centiva Capital opened a new position in Regeneron Pharmaceuticals (REGN) in Q1 2026: 14,610 shares worth $11.3M. The stake represents 0.08% of the portfolio and ranks #164 among its holdings. This is a return to the name: Centiva Capital previously reported a position in REGN as recently as Q2 2025.

Centiva Capital first reported a position in REGN in Q4 2018 and has held it in 18 quarters since. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Centiva Capital held 14,610 shares of Regeneron Pharmaceuticals worth $11.3M as of Q1 2026.
  • Regeneron Pharmaceuticals was a new Centiva Capital position in Q1 2026.
  • Regeneron Pharmaceuticals made up 0.08% of Centiva Capital's portfolio in Q1 2026, its #164 holding.
  • Centiva Capital first reported a position in Regeneron Pharmaceuticals in Q4 2018 and has held it in 18 quarters since.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Centiva Capital's 13F filing for Q1 2026, filed 14 May 2026.